welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201
Wave Life Sciences Ltd., a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug designation and rare pediatric disease designation for WVE-210201 for the treatment of Duchenne muscular dystrophy (DMD). The European Commission previously granted orphan drug designation for WVE-210201 in July 2018.
rareRelated
-
Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial DesignWave Life Sciences Ltd., a clinical-stag...
-
Antisense Therapeutics to commence muscular dystrophy trialsAntisense Therapeutics is planning to un...
-
A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian S...This is a phase III, multicenter, open-l...
-
The Duchenne RegistryThe Duchenne Registry is an online, pati...
-
Magnetic Resonance and Optical Imaging of Dystrophic and Damaged MuscleThe purpose of this research study is to...
-
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystroph...The proposed clinical trial is an outgro...
-
Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular DystrophyResearchers at Children's Hospital Bosto...
-
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship ProgramCAMBRIDGE, Mass., Sept. 05, 2019 (GLOB...
-
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
-
Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutati...Ataluren is conditionally approved by th...
